Skip to main content

St. Louis cancer drug startup Arch Oncology lays off staff, vacates Cortex office

The moves — which one former executive described as a "wind-down situation" — marks an abrupt development for the company, which in recent years has been considered one of St. Louis' most promising startups as it advanced its lead drug candidate into clinical trials to treat cancer patients.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.